journal
https://read.qxmd.com/read/38872511/outcomes-of-therapeutic-plasma-exchange-for-the-treatment-of-patients-with-multiple-myeloma-cast-nephropathy
#1
MULTICENTER STUDY
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, Nnaemeka Ibeh, Fauzia Ullah, Aimaz Afrough, Sandra Mazzoni, Ali Mehdi, Joslyn Rudoni, Shahzad Raza, Nicole De Simone, Louis Williams, Adeel Khan, Aliya Rashid, Mikhaila Rice, Kristin Ricci, Christy Samaras, Jason Valent, Larry D Anderson, Faiz Anwer, Gurbakhash Kaur, Jack Khouri
Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell-directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi-institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC...
July 2024: Hematological Oncology
https://read.qxmd.com/read/38861665/correction-to-real-life-study-on-the-use-of-response-adapted-therapy-in-patients-with-hodgkin-lymphoma-results-from-a-multicenter-experience
#2
(no author information available yet)
No abstract text is available yet for this article.
July 2024: Hematological Oncology
https://read.qxmd.com/read/38852069/clonal-dynamics-of-richter-transformation-in-chronic-lymphocytic-leukemia
#3
LETTER
Hanyin Wang, Shulan Tian, Charla R Secreto, Sutapa Sinha, Min Shi, Timothy Call, Yucai Wang, Sameer A Parikh, Saad S Kenderian, Rong He, Jose F Leis, Daniel L VanDyke, Eric W Klee, Susan L Slager, Esteban Braggio, Huihuang Yan, Wei Ding
No abstract text is available yet for this article.
July 2024: Hematological Oncology
https://read.qxmd.com/read/38847437/strategies-for-overcoming-resistance-to-bruton-s-tyrosine-kinase-inhibitor-zanubrutinib
#4
REVIEW
Hana Dostálová, Vladimír Kryštof
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell malignancies. They target BTK, a key effector in the B-cell receptor (BCR) signaling pathway, crucial for B-cell survival and proliferation. The first-in-class irreversible BTK inhibitor, ibrutinib, was approved for various B-cell malignancies but has limitations due to off-target effects. Second-generation inhibitors, such as acalabrutinib and zanubrutinib, offer improved selectivity and reduced side effects. However, resistance to BTK inhibitors, driven by BTK mutations, remains a challenge...
July 2024: Hematological Oncology
https://read.qxmd.com/read/38847317/safety-and-effectiveness-of-mogamulizumab-in-relapsed-or-refractory-cc-chemokine-receptor-4-positive-peripheral-t-cell-lymphoma-and-relapsed-or-refractory-cutaneous-t-cell-lymphoma-a-post-marketing-surveillance-in-japan
#5
JOURNAL ARTICLE
Kenji Ishitsuka, Tomoharu Yasukawa, Yukie Tsuji
Mogamulizumab is a humanized antibody targeting CC chemokine receptor 4 (CCR4). This post-marketing surveillance was conducted in Japan as a regulatory requirement from 2014 to 2020 to ensure the safety and effectiveness of mogamulizumab in patients with relapsed or refractory (r/r) CCR4-positive peripheral T-cell lymphoma (PTCL) or r/r cutaneous T-cell lymphoma (CTCL). Safety and effectiveness data were collected for up to 31 weeks after treatment initiation. A total of 142 patients were registered; safety was evaluated in 136 patients...
July 2024: Hematological Oncology
https://read.qxmd.com/read/38824453/a-real-life-study-of-daratumumab-combinations-in-newly-diagnosed-patients-with-light-chain-al-amyloidosis
#6
JOURNAL ARTICLE
Claudia Bellofiore, Pietro Benvenuti, Roberto Mina, Marco Basset, Andrea Foli, Martina Nanci, Mario Nuvolone, Gianluigi Guida, Andrea Attanasio, Roberta Mussinelli, Silvia Mangiacavalli, Claudio Salvatore Cartia, Valeria Masoni, Michele Palumbo, Lorenzo Cani, Stefania Oliva, Ugo Consoli, Concetta Conticello, Francesco Di Raimondo, Luca Arcaini, Sara Bringhen, Giampaolo Merlini, Giovanni Palladini, Paolo Milani
Daratumumab-based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real-world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including subjects with IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered with bortezomib in 50 (56%) patients, lenalidomide in 31 (35%), and monotherapy in 7 (8%)...
July 2024: Hematological Oncology
https://read.qxmd.com/read/38819002/metabolic-pathway-based-subtyping-reveals-distinct-microenvironmental-states-associated-with-diffuse-large-b-cell-lymphoma-outcomes
#7
JOURNAL ARTICLE
Xiaohui Wang, Hengqi Liu, Yue Fei, Zheng Song, Xiangrui Meng, Jingwei Yu, Xia Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianhuo Wang, Huilai Zhang
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease that requires personalized clinical treatment. Assigning patients to different risk categories and cytogenetic abnormality and genetic mutation groups has been widely applied for prognostic stratification of DLBCL. Increasing evidence has demonstrated that dysregulated metabolic processes contribute to the initiation and progression of DLBCL. Metabolic competition within the tumor microenvironment is also known to influence immune cell metabolism...
July 2024: Hematological Oncology
https://read.qxmd.com/read/38818978/elotuzumab-plus-pomalidomide-and-dexamethasone-in-relapsed-refractory-multiple-myeloma-extended-follow-up-of-a-multicenter-retrospective-real-world-experience-with-321-cases-outside-of-controlled-clinical-trials
#8
MULTICENTER STUDY
Enrica Antonia Martino, Salvatore Palmieri, Monica Galli, Daniele Derudas, Roberto Mina, Roberta Della Pepa, Renato Zambello, Ernesto Vigna, Antonella Bruzzese, Silvia Mangiacavalli, Elena Zamagni, Catello Califano, Maurizio Musso, Concetta Conticello, Claudio Cerchione, Giuseppe Mele, Nicola Di Renzo, Massimo Offidani, Giuseppe Tarantini, Gloria Margiotta Casaluci, Angela Rago, Roberto Ria, Giuseppina Uccello, Gregorio Barilà, Gaetano Palumbo, Loredana Pettine, Iolanda Donatella Vincelli, Marino Brunori, Fabrizio Accardi, Valeria Amico, Angela Amendola, Raffaele Fontana, Velia Bongarzoni, Bernardo Rossini, Emilia Cotzia, Alessandro Gozzetti, Rita Rizzi, Nicola Sgherza, Giovanni Reddiconto, Antonio Maroccia, Luca Franceschini, Giuseppe Bertuglia, Davide Nappi, Emiliano Barbieri, Barbara Gamberi, Maria Teresa Petrucci, Francesco Di Raimondo, Antonino Neri, Fortunato Morabito, Pellegrino Musto, Massimo Gentile
The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18-month follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers...
July 2024: Hematological Oncology
https://read.qxmd.com/read/38775115/flt3-itd-regulation-of-the-endoplasmic-reticulum-functions-in-acute-myeloid-leukemia
#9
JOURNAL ARTICLE
María Turos-Cabal, Ana M Sánchez-Sánchez, Noelia Puente-Moncada, Federico Herrera, Isaac Antolin, Carmen Rodríguez, Vanesa Martín
The FLT3-ITD mutation represents the most frequent genetic alteration in newly diagnosed acute myeloid leukemia (AML) patient and is associated with poor prognosis. Mutation result in the retention of a constitutively active form of this receptor in the endoplasmic reticulum (ER) and the subsequent modification of its downstream effectors. Here, we assessed the impact of such retention on ER homeostasis and found that mutant cells present lower levels of ER stress due to the overexpression of ERO1α, one of the main proteins of the protein folding machinery at the ER...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38741354/real-world-data-on-diagnostics-treatment-and-outcomes-of-patients-with-hairy-cell-leukemia-the-hcl-cllear-study
#10
JOURNAL ARTICLE
Anna Panovská, Pavel Žák, Tereza Jurková, Tomáš Arpáš, Yvona Brychtová, Alžběta Vašíková, Viera Hrabčáková, Adéla Prchlíková, Martina Filipová, Michael Doubek
Hairy cell leukemia (HCL) and HCL-like disorders have to be distinguished because of their different biology and treatment response. Thus, we conducted a retrospective study on patients with HCL and hairy cell leukemia variant (HCLv) to assess diagnostic algorithms and treatment outcomes in a real-world setting. We analyzed 225 HCL and 26 HCLv patients with median follow-up of 67.9 months (HCL) and 20.1 months (HCLv). Median age at diagnosis was 56.2 (HCL) and 69.5 years (HCLv), male predominance was observed in both groups (76...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38726682/prognostic-relevance-of-circulating-lymphoma-cells-at-diagnosis-in-newly-diagnosed-follicular-lymphoma-patients
#11
JOURNAL ARTICLE
Kaitlin Annunzio, Subodh Bhatta, Walter Hanel, Qiuhong Zhao, Mackenzie Owen, Havi Rosen, Timothy J Voorhees, David A Bond, Yazeed Sawalha, Audrey M Sigmund, Lapo Alinari, Robert A Baiocchi, Kami J Maddocks, Daniel Jones, Beth Christian, Narendranath Epperla
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma. Circulating lymphoma (CL) cells can be seen at diagnosis in some FL patients, however, previous studies evaluating this have shown mixed results. Therefore, we sought to evaluate the impact of CL at diagnosis on outcomes in patients with newly diagnosed FL using data from a single center. Patients were divided into CL+ and CL- based on immunophenotyping via peripheral blood (PB) flow cytometry. CL was defined as detectable clonally restricted B-cells that matched the actual or expected B-cell immunophenotype of FL...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38711253/a-phase-3b-study-of-venetoclax-and-azacitidine-or-decitabine-in-an-outpatient-setting-in-patients-with-acute-myeloid-leukemia
#12
MULTICENTER STUDY
Sudhir Manda, Bertrand M Anz, Christopher Benton, E Randolph Broun, Habte A Yimer, John S Renshaw, George Geils, Jesus Berdeja, Jose Cruz, Jason M Melear, Suzanne Fanning, Luke Fletcher, Yukun Li, Yinghui Duan, Michael E Werner, Jalaja Potluri, Madhavi V Pai, William B Donnellan
Venetoclax, a highly selective BCL-2 inhibitor, combined with hypomethylating agents (HMAs) azacitidine or decitabine, is approved for the treatment of newly diagnosed acute myeloid leukemia (ND AML) in patients who are ineligible to receive intensive chemotherapy. Previous clinical studies initiated venetoclax plus HMA in an inpatient setting owing to concerns of tumor lysis syndrome (TLS). This study (NCT03941964) evaluated the efficacy and safety of venetoclax plus HMA in a United States community-based outpatient setting in patients with ND AML (N = 60) who were treatment naïve for AML, ineligible to receive intensive chemotherapy, had no evidence of spontaneous TLS at screening, and were deemed as appropriate candidates for outpatient initiation of venetoclax plus HMA by the investigator...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38685583/retraction
#13
(no author information available yet)
No abstract text is available yet for this article.
May 2024: Hematological Oncology
https://read.qxmd.com/read/38682493/comparison-between-indolent-systemic-mastocytosis-and-clonal-mast-cell-disease-not-meeting-who-diagnostic-criteria-a-nationwide-multicenter-retrospective-analysis
#14
MULTICENTER STUDY
Mariarita Sciumè, Fabio Serpenti, Roberta Zanotti, Patrizia Bonadonna, Ilaria Tanasi, Lara Crosera, Chiara Elena, Francesco Mannelli, Francesca Crupi, Cristina Papayannidis, Chiara Sartor, Simona Soverini, Michela Rondoni, Cristina Eller-Vainicher, Valerio Pravettoni, Federica Rivolta, Silvia Alberti Violetti, Giorgio Alberto Croci, Anna Chiara Migliorini, Niccolò Bolli, Diana Giannarelli, Federica Irene Grifoni
No abstract text is available yet for this article.
May 2024: Hematological Oncology
https://read.qxmd.com/read/38676394/treatment-patterns-clinical-outcomes-and-gene-mutation-characteristics-of-hepatitis-b-virus-associated-mantle-cell-lymphoma
#15
JOURNAL ARTICLE
Jiangfang Feng, Yue Fei, Meng Gao, Xiangrui Meng, Dongfeng Zeng, Dehui Zou, Haige Ye, Yun Liang, Xiuhua Sun, Rong Liang, Hui Zhou, Xianhuo Wang, Huilai Zhang
Mantle cell lymphoma (MCL) is an uncommon and incurable B-cell lymphoma subtype that has an aggressive course. Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas, and is characterized by distinct clinical and genetic features. Here, we showed that 9.5% of MCL Chinese patients were hepatitis B surface antigen positive (HBsAg+ ). Compared to HBsAg-negative (HBsAg- ) patients, HBsAg+ MCL patients had a greater incidence of elevated lactate dehydrogenase (LDH), but no difference was observed in the other clinical characteristics, including sex, age, ECOG ps, Ann Arbor stage, MIPI, extranodal involvement and Ki-67...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38661222/erratum-to-reply-to-successful-early-use-of-anti-sars-cov-2-monoclonal-neutralizing-antibodies-in-sars-cov-2-infected-hematological-patients-a-czech-multicenter-experience-a-case-series-of-sars-cov-2-omicron-infection-and-aggressive-lymphoma-in-the-sotrovimab
#16
https://read.qxmd.com/read/38661120/real-life-study-on-the-use-of-response-adapted-therapy-in-patients-with-hodgkin-lymphoma-results-from-a-multicenter-experience
#17
MULTICENTER STUDY
Vittorio Ruggero Zilioli, Emanuele Cencini, Sonya De Lorenzo, Luca Pezzullo, Michele Merli, Flavia Rivellini, Cristina Muzi, Barbieri Emiliano, Luigi Marcheselli, Stefano Luminari
Few data are known regarding the use of interim positron emission tomography (iPET) after the first two cycles (iPET2) of chemotherapy in treatment-naïve classical Hodgkin lymphoma (cHL) in routine clinical practice, and about the real-life adoption of intensification strategies for iPET positive patients. We conducted a multicenter retrospective study on cHL to investigate the use of iPET in the real-life setting, its prognostic role and outcomes of patients early shifted to intensification. Six hundreds and forty-one patients were enrolled (62% had advanced stage)...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38650582/discovery-science-highlights-from-the-17th-international-conference-on-malignant-lymphoma
#18
JOURNAL ARTICLE
Gabriela Forestieri, Joyce Marques de Almeida, Sara Napoli, Deborah Piffaretti, Chiara Tarantelli, Fangwen Zhang, Afua Adjeiwaa Mensah
No abstract text is available yet for this article.
May 2024: Hematological Oncology
https://read.qxmd.com/read/38650534/future-perspectives-of-radiation-therapy-for-hodgkin-lymphoma-risk-adapted-response-adapted-and-safer-than-before
#19
REVIEW
Jessica Saddi, Amelia Barcellini, Manuel Gotti, Alessandro Mazzacane, Alessandra Tolva, Tanja Lazic, Luca Arcaini, Marco Zecca, Ester Orlandi, Andrea Riccardo Filippi
Classical Hodgkin lymphoma is a lymphoproliferative disease with a good prognosis mainly seen in young people. Nevertheless secondary malignancy, cardiac disease and infertility may affect the long survivors with significant impact on quality of life, morbidity and overall survival. In the last decades several treatment strategies were evaluated to reduce the toxicity of first line treatment such as avoiding radiotherapy or its reduction in terms of dosage and extension. Many trials including interim Positron Emission Tomography evaluation fail to compare efficacy between combined modality treatment versus chemotherapy alone in particular in early stage disease...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38606890/outcomes-after-treating-advanced-mantle-cell-lymphoma-in-a-low-income-group-at-a-latin-american-center-the-role-of-outpatient-hematopoietic-stem-cell-transplantation
#20
LETTER
José Carlos Jaime-Pérez, Marcela Hernández-Coronado, Mariana González-Treviño, Renata V Barragán-Longoria, Eugenia M Ramos-Dávila, David Gómez-Almaguer
No abstract text is available yet for this article.
May 2024: Hematological Oncology
journal
journal
28626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.